The National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine (SNM) are launching a collaboration to advance research for cancer imaging and therapies. Specifically, NCCN will work with SNM to qualify imaging sites for upcoming research projects utilizing molecular imaging in clinical trials.
NCCN, through its Oncology Research Program (ORP), obtains funding to support clinical trials at the 21 NCCN member institutions. These studies evaluate combinations and sequencing regimens of drugs, mechanisms of action of specific agents, or drug resistance or are directed toward exploring extended uses for specific agents.
As a new initiative of the ORP, the NCCN Specialized Imaging Research Consortium aims to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies.
"We know that historically it has been difficult to use molecular imaging agents in multicenter clinical trials due to a number of factors, including lack of qualified imaging sites and a lack of standardization, among others," said Dominique Delbeke, MD, SNM president. "SNM’s Clinical Trials Network helps to make this process easier."